Table 1.
Baseline characteristics in the one- and two-dose trials of Ad5-nCoV after propensity score matching.
| Low-dose group |
High-dose group |
|||||
|---|---|---|---|---|---|---|
| One-dose trial | Two-dose trial | p value | One-dose trial | Two-dose trial | p value | |
| N | 34 | 34 | 29 | 29 | ||
| Age, years | 51.3 (8.2) | 51.4 (8.0) | .964 | 60.9 (5.6) | 60.5 (4.2) | .770 |
| Sex | ||||||
| Male | 16 (47.1%) | 13 (38.2%) | .462 | 16 (55.2%) | 18 (62.1%) | .594 |
| Body-mass index, kg/m2 | 24.0 (2.5) | 24.5 (3.4) | .514 | 23.8 (2.5) | 24.0 (2.7) | .799 |
| Pre-existing adenovirus type-5 neutralizing antibody | ||||||
| ≤1:200, titer | 12 (35.3%) | 14 (41.2%) | .618 | 13 (44.8%) | 11 (37.9%) | .524 |
| >1:200, titer | 22 (64.7%) | 20 (58.8%) | 16 (55.2%) | 18 (65.5%) | ||
Data are mean (SD), number of participants (%) and p value. SD = standard deviation. BMI = body-mass index. N = the number of participants after propensity score matching.